Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.
作者信息
Mack Philip C, Hirsch Fred R, Bunn Paul A, Minna John D
机构信息
Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY.
Department of Internal Medicine, University of Colorado Cancer Center, Denver, CO.
出版信息
J Clin Oncol. 2022 Nov 20;40(33):3787-3789. doi: 10.1200/JCO.22.01136. Epub 2022 Jun 27.
Abstract
摘要
相似文献
1
Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.肺癌患者新冠病毒疫苗接种的纵向分析：抗体反应和变异株特异性中和作用
J Clin Oncol. 2022 Nov 20;40(33):3787-3789. doi: 10.1200/JCO.22.01136. Epub 2022 Jun 27.
2
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.肺癌患者中纵向新冠疫苗接种诱导的抗体反应和对奥密克戎的中和作用
Cancer Cell. 2022 Jun 13;40(6):575-577. doi: 10.1016/j.ccell.2022.04.012. Epub 2022 Apr 20.
3
Antibody responses to Sputnik Vaccination in naïve and COVID 19-recovered vaccine recipients, India.印度初免和新冠康复疫苗接种者对卫星五号疫苗的抗体反应。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac040.
4
Reply to letter to the editor "antibody responses to second doses of COVID-19 vaccination in lung cancer patients: Comment".对编辑来信《肺癌患者对第二剂新冠疫苗接种的抗体反应：评论》的回复
Respir Investig. 2023 May;61(3):347-348. doi: 10.1016/j.resinv.2023.02.004. Epub 2023 Mar 7.
5
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients: comment.肺癌患者对第二剂新冠疫苗接种的抗体反应：评论
Respir Investig. 2023 May;61(3):332. doi: 10.1016/j.resinv.2023.02.001. Epub 2023 Mar 1.
6
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.卫星五号疫苗接种后的纵向研究显示，随着时间的推移，SARS-CoV-2 中和抗体具有持久性，并且对病毒变异的中和逃逸能力降低。
mBio. 2022 Feb 22;13(1):e0344221. doi: 10.1128/mbio.03442-21. Epub 2022 Jan 25.
7
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
8
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.癌症治疗患者接种 COVID-19 疫苗后的抗体和 T 细胞反应。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004766.
9
Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.同源加强 COVID-19 疫苗接种在卫生保健工作者中引发了强烈的免疫反应。
Diagn Microbiol Infect Dis. 2022 Oct;104(2):115758. doi: 10.1016/j.diagmicrobio.2022.115758. Epub 2022 Jul 1.
10
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.接受抑制性抗逆转录病毒疗法的 HIV 感染者接种三剂新冠肺炎疫苗后的抗体反应持久性。
AIDS. 2023 Apr 1;37(5):709-721. doi: 10.1097/QAD.0000000000003469. Epub 2022 Dec 22.
引用本文的文献
1
In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients.在新冠疫情期间：癌症患者研究中的挑战、成功经验与教训
J Natl Cancer Inst. 2025 Aug 1;117(8):1547-1556. doi: 10.1093/jnci/djaf073.
本文引用的文献
1
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.肺癌患者初次免疫和加强免疫后对 COVID-19 mRNA 疫苗的抗体反应：对 SARS-CoV-2 WT 病毒和奥密克戎变异株的反应性。
J Clin Oncol. 2022 Nov 20;40(33):3808-3816. doi: 10.1200/JCO.21.02986. Epub 2022 Jun 27.
2
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.肺癌患者中纵向新冠疫苗接种诱导的抗体反应和对奥密克戎的中和作用
Cancer Cell. 2022 Jun 13;40(6):575-577. doi: 10.1016/j.ccell.2022.04.012. Epub 2022 Apr 20.
3
The Effect of Smoking on Humoral Response to COVID-19 Vaccines: A Systematic Review of Epidemiological Studies.吸烟对新冠疫苗体液免疫反应的影响：流行病学研究的系统评价
Vaccines (Basel). 2022 Feb 16;10(2):303. doi: 10.3390/vaccines10020303.
4
Three-dose vaccination elicits neutralising antibodies against omicron.三剂疫苗接种可引发针对奥密克戎的中和抗体。
Lancet. 2022 Feb 19;399(10326):715-717. doi: 10.1016/S0140-6736(22)00092-7. Epub 2022 Jan 19.
5
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
6
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
7
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.严重急性呼吸综合征冠状病毒 2 疫苗在胸部癌症患者中的疗效：一项支持在两剂疫苗接种后血清学应答轻微的患者中接种第三剂疫苗的前瞻性研究。
J Thorac Oncol. 2022 Feb;17(2):239-251. doi: 10.1016/j.jtho.2021.10.015. Epub 2021 Nov 16.
8
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.癌症患者中 SARS-CoV-2 疫苗的免疫原性和反应原性：CANVAX 队列研究。
J Clin Oncol. 2022 Jan 1;40(1):12-23. doi: 10.1200/JCO.21.01891. Epub 2021 Nov 9.
9
Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group.癌症患者对SARS-CoV-2疫苗的反应（ReCOVer研究）：希腊合作肿瘤学组的一项前瞻性队列研究
Cancers (Basel). 2021 Sep 15;13(18):4621. doi: 10.3390/cancers13184621.
10
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis.实体瘤或血液系统恶性肿瘤合并 SARS-CoV-2 感染的成年患者的死亡率：一项系统评价和荟萃分析，重点关注肺癌和乳腺癌。
Crit Rev Oncol Hematol. 2021 Jul;163:103365. doi: 10.1016/j.critrevonc.2021.103365. Epub 2021 May 27.
Zotero 插件